Microenvironmental stimuli affect Endothelin-1 signaling responsible for invasiveness and osteomimicry of bone metastasis from breast cancer

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 4, 2014, Pages 815-826

  Bendinelli, Paola ^a   Maroni, Paola ^b   Matteucci, Emanuela ^a   Luzzati, Alessandro ^b   Perrucchini, Giuseppe ^b   Desiderio, Maria Alfonsina ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

Bone metastasis; Endothelin 1 axis; Growth factors; Microenvironment; Osteomimicry

Indexed keywords

BONE METASTASIS; ENDOTHELIN-1 AXIS; GROWTH FACTORS; MICROENVIRONMENT; OSTEOMIMICRY;

BONE NEOPLASMS; BREAST NEOPLASMS; ENDOTHELIN-1; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; NEOPLASM INVASIVENESS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY;

EID: 84893758552     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.12.015     Document Type: Article

References (58)

1. Clezardin P., Teti A. Bone metastasis: pathogenesis and therapeutic implication. Clin. Exp. Metastasis 2007, 24:599-608.
2. Said N., Theodorescu D. Permissive role of Endothelin receptors in tumor metastasis. Life Sci. 2012, 91:522-527.
3. Adwan H., Bäuerle T.J., Berger M.R. Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB231 human breast cancer cells. Cancer Gene Ther. 2004, 11:109-120.
4. Campo McKnight D.A., Sonoski D.M., Koblinski J.E., Gay C.V. Roles of osteonectin in the migration of breast cancer cells into bone. J. Cell. Biochem. 2006, 97:288-302.
5. Cox R.F., Jenkinson A., Pohl K., O'Brien F.J., Morgan M.P. Osteomimicry of mammary adenocarcinoma cells in vitro; increased expression of bone matrix proteins and proliferation within a 3D collagen environment. PLoS One 2012, 7:e41679.
6. Barnes G.L., Javed A., Waller S.M., Kamal M.H., Hebert K.E., Hassan M.Q., Bellahcene A., Van Wijnen A.J., Young M.F., Lian J.B., Stein J.S., Gerstenfeld L.C. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res. 2003, 63:2631-2637.
7. Lowery F.J., Yu D. Growth factor signaling in metastasis: current understanding and future opportunities. Cancer Metastasis Rev. 2012, 31:479-491.
8. Weber C.E., Kuo P.C. The tumor microenvironment. Surg. Oncol. 2012, 21:172-177.
9. Matteucci E., Maroni P., Luzzati A., Perrucchini G., Bendinelli P., Desiderio M.A. Bone metastatic process of breast cancer involves methylation state affecting E-cadherin expression through TAZ and WWOX nuclear effectors. Eur. J. Cancer 2013, 49:231-244.
10. Santini D., Galluzzo S., Zoccoli A., Pantano F., Fratto M.E., Vincenzi B., Lombardi L., Guicciardino C., Silvestris N., Riva E., Rizzo S., Russo A., Maiello E., Colucci G., Tonini G. New molecular targets in bone metastasis. Cancer Treat. Rev. 2010, 36:S6-S10.
11. Zhang X.H., Wang Q., Gerald W., Hudis L., Norton M., Smid J.A., Foekens J.A., Massagué J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16:67-78.
12. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordón-Cardo C., Guise T.A., Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
13. Previdi S., Maroni P., Matteucci E., Broggini M., Bendinelli P., Desiderio M.A. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and β-catenin/Wnt pathways. Eur. J. Cancer 2010, 46:1679-1691.
14. Maroni P., Bendinelli P., Matteucci E., Locatelli A., Nakamura T., Scita G., Desiderio M.A. Osteolytic bone metastasis is hampered by oppositely impinging on autophagy/anoikis and ossification biological processes. Cell Death Dis. 2013, 10.1038/cddis.2013.465.
15. Rodríguez-Pascual F., Redondo-Horcajo M., Lamas S. Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-β-mediated induction of endothelin-1 expression. Circ. Res. 2003, 92:1288-1295.
16. Overall C.M., Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 2006, 6:227-239.
17. Wu M.H., Lo J.F., Kuo C.H., Lin J.A., Lin Y.M., Chen L.M., Tsai F.J., Tsai C.H., Huang C.Y., Tang C.H. Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways. J. Cell. Physiol. 2012, 227:3016-3026.
18. Virk M.S., Lieberman J.R. Tumor metastasis to bone. Arthritis Res. Ther. 2007, 9(Suppl. 1):S5.
19. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
20. Maroni P., Matteucci E., Luzzati A., Perrucchini G., Bendinelli P., Desiderio M.A. Nuclear co-localization and functional interaction of COX-2 and HIF-1α characterize bone metastasis of human breast carcinoma. Breast Cancer Res. Treat. 2011, 129:433-450.
21. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009, 28:15-33.
22. Gilkes D.M., Semenza G.L. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol. 2013, 9:1623-1636.
23. Bendinelli P., Maroni P., Matteucci E., Luzzati A., Perrucchini G., Desiderio M.A. Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer. Eur. J. Cancer 2013, 49:2608-2618.
24. Rosanò L., Spinella F., Di Castro V., Nicotra M.R., Dedhar S., de Herreros A.G., Natali P.G., Bagnato A. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res. 2005, 65:11649-11657.
25. Rosanò L., Spinella F., Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2013, 13:637-651.
26. Medinger M., Adler C.P., Schmidt-Gersbach C., Soltau J., Droll A., Unger C., Drevs J. Angiogenesis and the ET-1/ETA receptor system: immunohistochemical expression analysis in bone metastases from patients with different primary tumors. Angiogenesis 2003, 6:225-231.
27. Matteucci E., Maroni P., Locatelli A., Bendinelli P., Desiderio M.A. Epigenetic control of endothelin-1 axis affects invasiveness of breast carcinoma cells with bone tropism. Exp. Cell Res. 2013, 319:1865-1874.
28. Wülfing P., Diallo R., Kersting C., Wülfing C., Poremba C., Rody A., Greb R.R., Böcker W., Kiesel L. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin. Cancer Res. 2003, 9:4125-4131.
29. Carducci M.A., Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin. Cancer Res. 2006, 12:6296s-6300s.
30. Ridolfi E., Matteucci E., Maroni P., Desiderio M.A. Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs. Br. J. Cancer 2008, 99:1623-1634.
31. Kandalaft L.E., Facciabene A., Buckanovich R.J., Coukos G. Endothelin B receptor, a new target in cancer immune therapy. Clin. Cancer Res. 2009, 15:4521-4528.
32. Ding J., Ghali O., Lencel P., Broux O., Chauveau C., Devedjian J.C., Hardouin P., Magne D. TNF-alpha and IL-1beta inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci. 2009, 84:499-504.
33. Smollich M., Wülfing P. Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers. Expert. Rev. Anticancer. Ther. 2008, 8:1481-1493.
34. Mauschitz R., Cervar M., Hahn T., Pürstner P., Desoye G. Self-regulation of the endothelin receptor system in choriocarcinoma cells. Biochim. Biophys. Acta 2000, 1502:224-234.
35. Smollich M., Götte M., Fischgräbe J., Macedo L.F., Brodie A., Chen S., Radke I., Kiesel L., Wülfing P. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. Breast Cancer Res. Treat. 2010, 123:345-357.
36. Boivin B., Chevalier D., Villeneuve L.R., Rousseau E., Allen B.G. Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. J. Biol. Chem. 2003, 278:29153-29163.
37. B receptors regulates the abundance of ET-1 mRNA in vascular endothelial cells. Br. J. Pharmacol. 2008, 153:1420-1431.
38. Reimunde F.M., Castañares C., Redondo-Horcajo M., Lamas S., Rodríguez-Pascual F. Endothelin-1 expression is strongly repressed by AU-rich elements in the 3'-untranslated region of the gene. Biochem. J. 2005, 387:763-772.
39. He F., Li J., Mu Y., Kuruba R., Ma Z., Wilson A. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ. Res. 2006, 98:192-199.
40. Pratap J., Javed A., Languino L.R., van Wijnen A.J., Stein J.L., Stein G.S., Lian J.B. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol. Cell. Biol. 2005, 25:8581-8591.
41. von Brandenstein M., Depping R., Schäfer E., Dienes H.-P., Fries J.W.U. Protein kinase C α regulates nuclear pri-microRNA 15a release as part of endothelin signaling. Biochim. Biophys. Acta 2011, 1813:1793-1802.
42. Vonica A., Weng W., Gumbiner B.M., Venuti J.M. TCF is the nuclear effector of the beta-catenin signal that patterns the sea urchin animal-vegetal axis. Dev. Biol. 2000, 217:230-243.
43. Guise T.A., Kozlow W.M., Heras-Herzig A., Padalecki S.S., Yin J.J., Chirgwin J.M. Molecular mechanisms of breast cancer metastases to bone. Clin. Breast Cancer 2005, 5:S46-S53.
44. Kao J., Salari K., Bocanegra M., Choi Y.L., Girard L., Gandhi J. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009, 4:e6146.
45. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13:4429-4434.
46. Hagemann T., Binder C., Binder L., Pukrop T., Trümper L., Grimshaw M.J. Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol. 2005, 24:766-776.
47. Wülfing P., Tio J., Kersting C., Sonntag B., Buerger H., Wülfing C., Euler U., Boecker W., Tulusan A.H., Kiesel L. Expression of endothelin-A-receptor predicts unfavourable response to neoadjuvant chemotherapy in locally advanced breast cancer. Br. J. Cancer 2004, 91:434-440.
48. Grimshaw M.J., Hagemann T., Ayhan A., Gillett C.E., Binder C., Balkwill F.R. A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res. 2004, 64:2461-2468.
49. Yoneda T., Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem. Biophys. Res. Commun. 2005, 328:679-687.
50. Papachristou D.J., Basdra E.K., Papavassiliou A.G. Bone metastases: molecular mechanisms and novel therapeutic interventions. Med. Res. Rev. 2012, 32:611-636.
51. Gunasinghe N.P.A.D., Wells A., Thompson E.W., Hugo H.J. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonization in breast cancer. Cancer Metastasis Rev. 2012, 31:469-478.
52. Yamashita K., Discher D.J., Hu J., Bishopric N.H., Webster K.A. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J. Biol. Chem. 2001, 276:12645-12653.
53. Lim S.O., Gu J.M., Kim M.S., Kim H.S., Park Y.N., Park C.K., Cho J.W., Park Y.M., Jung G. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 2008, 135:2128-2140.
54. Stow L.R., Jacobs M.E., Wingo C.S., Cain B.D. Endothelin-1 gene regulation. FASEB J. 2011, 25:16-28.
55. Paoli P., Giannoni E., Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim. Biophys. Acta 2013, 10.1016/j.bbamcr.2013.06.026.
56. Hassan M.Q., Maeda Y., Taipaleenmaki H., Zhang W., Jafferji M., Gordon J.A., Li Z., Croce C.M., van Wijnen A.J., Stein J.L., Stein G.S., Lian J.B. miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J. Biol. Chem. 2012, 287:42084-42092.
57. Desiderio M.A. Hepatocyte growth factor in invasive growth of carcinomas. Cell. Mol. Life Sci. 2007, 64:1341-1354.
58. Wiercinska E., Naber H.P.H., Pardali E., van der Pluijm G., van Dam H., ten Dijke P. The TGF-β/Smad pathway induces breast cancer cell invasion trough the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res. Treat. 2011, 128:657-666.